参考文献

2020-10-14

1: Kmeid J, Kanafani ZA. Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review. Core Evid. 2015 Feb 11;10:39-47. doi: 10.2147/CE.S51284. eCollection 2015. Review. PubMed PMID: 25709561; PubMed Central PMCID: PMC4334198.

2: Das B, Sarkar C, Schachter J. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens. Pak J Pharm Sci. 2013 Sep;26(5):1045-55. Review. PubMed PMID: 24035967.

3: Karaoui LR, El-Lababidi R, Chahine EB. Oritavancin: an investigational lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2013 Jan 1;70(1):23-33. doi: 10.2146/ajhp110572. Review. PubMed PMID: 23261897.

4: Bouza E, Burillo A. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Int J Antimicrob Agents. 2010 Nov;36(5):401-7. doi: 10.1016/j.ijantimicag.2010.06.048. Epub 2010 Aug 21. Review. PubMed PMID: 20729040.

5: Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000. Review. Erratum in: Drugs. 2011 Mar 26;71(5):526. PubMed PMID: 20426497.

6: Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010 Jan;30(1):80-94. doi: 10.1592/phco.30.1.80. Review. PubMed PMID: 20030476.

7: Anderson DL. Oritavancin for skin infections. Drugs Today (Barc). 2008 Aug;44(8):563-75. doi: 10.1358/dot.2008.44.8.1250078. Review. PubMed PMID: 18846268.

8: Crandon J, Nicolau DP. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol. 2008 Jun;3(3):251-63. doi: 10.2217/17460913.3.3.251. Review. PubMed PMID: 18505390.

9: Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opin Investig Drugs. 2008 Feb;17(2):225-43. doi: 10.1517/13543784.17.2.225. Review. PubMed PMID: 18230056.

10: Ward KE, Mersfelder TL, LaPlante KL. Oritavancin--an investigational glycopeptide antibiotic. Expert Opin Investig Drugs. 2006 Apr;15(4):417-29. Review. PubMed PMID: 16548791.